Printer Friendly

Gamma Medica Partners with Einstein Medical Center in Philadelphia on Clinical LumaGEM Molecular Breast Imaging Technology Deployment.

M2 PHARMA-November 30, 2016-Gamma Medica Partners with Einstein Medical Center in Philadelphia on Clinical LumaGEM Molecular Breast Imaging Technology Deployment

(C)2016 M2 COMMUNICATIONS

- The Einstein Medical Center Philadelphia has committed to purchase Pennsylvania's first clinical LumaGEMMolecular Breast Imaging system, US-based molecular breast imaging technology specialist Gamma Medica said on Wednesday.

Gamma Medica's LumaGEM MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilising dual-head Digital Direct Conversion Gamma Imaging (DDCGI ) technology for molecular breast imaging.

With over 90% sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound.

MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer.

It is a proven supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection in women who are at a higher risk due to dense breast tissue.

Approximately 50% of US women are reported to have dense breast tissue, but many women do not realize they have dense breasts and if they do, they may not understand what it means for their increased risk of breast cancer.

Dense breast tissue is a risk factor and personalized screening is reported to be best practice in early detection.

Because dense breast tissue and cancer both appear white on mammograms, cancer detection through mammography alone is difficult and may lead to false negatives or delayed diagnoses.

Over 40,000 US women die from breast cancer annually, making early detection imperative.

While mammograms may fail to detect breast tumors due to tissue density, MBI highlights metabolic activity in these tumors despite breast density, leading to an earlier diagnosis.

A breakthrough retrospective clinical study published in the August issue of the American Journal of Roentgenology confirmed MBI's high incremental cancer detection rate: MBI was able to detect 7.7 cancers per 1,000 women screened compared to mammography.

Approximately 85% of these cancers were node negative, meaning they were detected at an earlier stage and presented a better prognosis.

To educate women about breast density and breast cancer screening options, Gamma Medica launched the Be Certaineducational campaign, which aims to provide the most accurate information for physicians, patients and caregivers.

In addition to education, Gamma Medica is committed to increasing the number of accurate early breast cancer screenings through installations at major facilities like Einstein Medical Center Philadelphia.

Einstein Healthcare Network marks its 150th anniversary in 2016, celebrating its journey from a 22-bed hospital to a comprehensive network of health providers serving Philadelphia and Montgomery County.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1U2PA
Date:Nov 30, 2016
Words:465
Previous Article:US FDA Clears ConvertX Nephroureteral Stent System.
Next Article:Biosurgery Market to Reach USD 27.78bn by 2021, MarketsandMarkets Predicts.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters